The patients’ background of this study is different from our study so that only three CAD patients (30%) were included and six patients (60%) were under insulin treatment protocol, while we recruited a more homogenous sample of CAD patients (three-vessel CAD accompanying with metabolic syndrome history but with controlled hypertension and blood glucose). The gene discussed is INS; the disease is coronary artery disorder.